About Us
Our Story
A science-driven oncology therapeutics company, we’re focused on the development of novel bispecific antibody drug conjugates (ADCs) that are designed to improve outcomes for cancer patients.
Accelerating Innovation in ADCs
At NEOK Bio, we’re driven to fulfill the vast, untapped potential of the ADC modality in oncology to rapidly and efficiently deliver transformative therapeutic benefits to cancer patients.
​​
Backed by ABL Bio, a pioneer and world-leader in antibody engineering via its advanced technology platform, NEOK is well-positioned to deliver cutting-edge, dual target ADCs that overcome the efficacy and safety challenges that have limited the effectiveness of conventional ADC therapies.
As Science Advances, We’re Leading the Way
Bispecific ADCs represent a significant advancement, providing the ability to target two complimentary antigens – potentially improving safety while enhancing the efficacy of ADCs in a wide range of solid tumors. Leveraging the robust capabilities of our next generation ADC platform technology, combined with our team’s proven scientific and drug development expertise, we aim to fulfill the potential of ADCs to make a meaningful difference in patients’ lives.
About Our Name
NEOK stands for a New Era Of Knowledge — a philosophy that drives everything we do. Our platform harnesses data, biology, and chemistry to deliver more precise, safer, and effective ADCs for patients with cancer. Our mission is simple yet bold: to turn deep knowledge into real therapeutic breakthroughs.